PERSPECTA

News from every angle

← Back to headlines

Incannex begins Phase 2 clinical trial for IHL-42X therapy

The biotech firm announced the dosing of the first patient in its DReAMzz study, marking a key milestone in the development of the investigational treatment.

25 Aug, 12:46 — 25 Aug, 12:46
PostShare

Sources

Showing 1 of 1 sources
taiwan-newsMostly Factual1d ago

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X - Taiwan News

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X  Taiwan News

Read full article →

Related Stories

FDA Approves Landmark Pancreatic Cancer Drug Daraxonrasib

15m ago

North Macedonia Reports Rising Number of West Nile Virus Cases

19m ago

Busy Philipps Reveals Rare Brain Tumor Diagnosis and Recent Surgeries

25m ago

French Court Rules Flight Attendant’s Breast Cancer Occupational

1h ago